5 completed, 3 not yet recruiting, 2 withdrawn, 1 terminated. 12 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 5, Not yet recruiting 3, Withdrawn 2, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Not yet recruiting 2, Completed 1, Withdrawn 1 |
Follow Liver Failure, Acute: new trials by email Literature Review of Liver Failure, Acute trials Research Report on Liver Failure, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial Umbilical cord Mesenchymal stem cell, Steroid, Standard Medical Treatment - Acute-On-Chronic Liver Failure | Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2028-01-01 | 2025-08-17 |
| Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF Low-dose experimental group, High-dose experimental group, Low-dose placebo control group - Acute-On-Chronic Liver Failure | Phase 2 / Phase 3 | Not yet recruiting | National Engineering Center of Cell Products | 96 | 2025-04-15 | 2025-03-19 |
| Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed Terlipressin Injectable Product - Acute on Chronic Liver Failure | Phase 2 / Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 60 | 2025-02-10 | 2025-02-07 |
| Plasma Exchange in Acute on Chronic Liver Failure Plasma exchange, Standard medical treatment - Cirrhosis, Liver, Acute-On-Chronic Liver Failure | Phase 3 | Unknown | Asian Institute of Gastroenterology, India | 130 | 2019-08-15 | 2019-08-09 |
| Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% SMT + PE-A 5%, Standard Medical Treatment - Acute-On-Chronic Liver Failure | Phase 3 | Terminated | Instituto Grifols, S.A. | 274 | 2019-06-17 | 2026-06-04 |
| 13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF 13C-Methacetin - Acute Liver Failure | Phase 2 / Phase 3 | Completed | University of Texas Southwestern Medical Center | 76 | 2016-06-10 | 2020-12-22 |
| Cardiox Liver Function Test Pivotal Trial 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose - Hepatic Failure, Liver Failure | Phase 3 | Withdrawn | Cardiox Corporation | 2015-11-01 | 2016-01-15 | |
| Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO), Placebo - Acute on Chronic Hepatic Failure | Phase 3 | Completed | Institute of Liver and Biliary Sciences, India | 55 | 2011-07-01 | 2016-12-06 |
| Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion ELAD (Extracorporeal Liver Assist System) - Acute Liver Failure | Phase 2 / Phase 3 | Withdrawn | Vital Therapies, Inc. | 2010-06-01 | 2013-12-04 | |
| The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure Molecular Adsorbent Recirculating System (MARS®) - Hepatitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 110 | 2004-08-01 | 2011-02-17 |
| N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure N-acetylcysteine, Placebo - Acute Liver Failure, Hepatic Encephalopathy | Phase 3 | Completed | University of Pittsburgh | 184 | 2000-01-01 | 2016-07-28 |
| Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen N-acetylcysteine (NAC), Placebo - Acute Liver Failure | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 173 | 1998-06-01 | 2017-10-13 |
Acute-On-Chronic Liver Failure (6) · Fibrosis (2) · Hepatic Encephalopathy (2) · Liver Failure (2) · Gastrointestinal Diseases (1) · Hepatitis (1) · Hepatitis C (1) · Hepatitis, Alcoholic (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Massive Hepatic Necrosis (1) · Rare Diseases (1)
Digestive System Diseases (12) · Hepatic Insufficiency (12) · Liver Diseases (11) · Liver Failure (10) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Brain Diseases (2) · Brain Diseases, Metabolic (2) · Central Nervous System Diseases (2) · Hepatitis (2) · Metabolic Diseases (2) · Nervous System Diseases (2) · Nutritional and Metabolic Diseases (2) · Alcohol-Induced Disorders (1)
Acetylcysteine (2) · Glucose (1) · Granulocyte Colony-Stimulating Factor (1) · Plasma Exchange (1) · Steroids (1) · Water (1)
Institute of Liver and Biliary Sciences, India (3) · Asian Institute of Gastroenterology, India (1) · Assistance Publique - Hôpitaux de Paris (1) · Cardiox Corporation (1) · Instituto Grifols, S.A. (1) · National Engineering Center of Cell Products (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · University of Pittsburgh (1) · University of Texas Southwestern Medical Center (1) · Vital Therapies, Inc. (1)
United States (5) · India (3) · France (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Canada (1) · Germany (1) · Italy (1) · Portugal (1) · Spain (1)
Dr. Shiv Kumar Sarin, DM (1) · Michael Jopling, MD (1) · Robert A Ashley (1) · Robert H Squires, M.D. (1) · Robert J. Fontana, MD (1) · Shiv Kumar Sarin, MD, DM (1) · William M. Lee, MD (1)
PMID 37183883, PMID 19524577, PMID 24126646, PMID 31421008
U01DK058369 (2), R01DK058369 (1), R03DK052827 (1), U01DK072146 (1)